Previous 10 | Next 10 |
Four times a year, I spend several hours combing through Form 13F filings from the hedge funds that specialize in M&A. I document and analyze which merger stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share it with everyo...
This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position ...
In my previous article , I highlighted the importance of investing in Amicus Therapeutics, a relatively safe stock with high growth potential. BioMarin Pharmaceutical ( BMRN ) is another such stock that has ticked all the boxes. The company has a robust commercialized portfolio, a strong R&...
Merger activity increased last week with four new deals announced and four deals closing. Deal Statistics: New Deals: The acquisition of Innophos Holdings ( IPHS ) by an affiliate of One Rock Capital Partners for $932 million or $32.00 per share in cash. The acquisition of C...
Roche ( RHHBY ) acquiring Spark ( ONCE ) is probably the M&A nail biter of 19'. This deal got extended several times with an FTC second request underway. The terms of the deal also made it clear that Roche could walk under circumstances where asset divestitures were requested (a common way...
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or...
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Aw...
Merger activity decreased last week, with one new deal announced and seven deals closing. Deal Statistics: New Deals: The acquisition of Ra Pharmaceuticals ([[RARX]]) by UCB for $2.1 billion, or $48.00 per share in cash. Deal Updates: On October 8, 2019, Prosperity Bancs...
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or...
News, Short Squeeze, Breakout and More Instantly...
Spark Therapeutics Inc. Company Name:
ONCE Stock Symbol:
NASDAQ Market:
Spark Therapeutics Inc. Website:
Genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So, what is genetics investing? When it comes to genetics investing, companies in this niche...
After big biopharma Astellas (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Aw...